The work presented here shows for the first time that liposomes can be used as antigen-producing artificial-cells for vaccination. AnExILs combine antigen-production, delivery and adjuvanticity in one system, making them more potent in inducing antibody responses compared to liposomal DNA vaccines as shown here. Still, the specificity of AnExILs is only determined by its genetic input which offers great flexibility in vaccine production and formulation. Preliminary data from our lab show that it is possible to store AnExILs lyophilized. Upon hydration with a DNA solution, the DNA is being transcribed and translated inside the rehydrated liposomes (data not shown). Such a universal vaccine platform may solve some of the problems of production lag-time with conventional vaccines (Hinman et al. 2006; DesRoches et al. 2005; Ulmer et al. 2006 ). Furthermore, it may allow easy production of personalized vaccines for e.g. cancer vaccination, in which the antigens are optimized for each individual (Poland et al. 2008) .